We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Technique Devised to Disable Cancer Cells’ Defenses Against Radiation

By LabMedica International staff writers
Posted on 05 Apr 2012
Researchers are developing a technique to remove cancer cells’ defenses against radiation. More...


Radiation chiefly kills cells by inducing DNA damage, so the goal of the technique is to sensitize cells to radiation by disabling their ability to repair DNA. The technique sneaks RNA molecules into cells that shut down genes needed for DNA repair. The still-investigational technology could potentially allow oncologists to boost the tumor-killing effects of radiation, while using lower doses and reducing injury to healthy tissues.

In the laboratory, the scientists utilized modified lentiviruses to introduce the RNA molecules. The same types of viruses have been used in gene therapy research. Dr. Wang reported that her team is now testing whether a small peptide tag can direct RNA to brain tumors instead. The results are published in the March 1, 2012, issue of the journal Cancer Research.

Ya Wang, MD, PhD, professor of radiation oncology at Emory University School of Medicine and director of the division of experimental radiation oncology at the Winship Cancer Institute (Atlanta, GA, USA) senior author of the study. The first author Dr. Zhiming Zheng, is now at Shandong University in China.

Dr. Zheng and his colleagues focused on two genes, XRCC2 and XRCC4, which encode proteins required for separate pathways of DNA repair. XRCC2 and XRCC4, in general, are both more active in tumor cells than in healthy cells.

In the past, using RNA interference (RNAi) techniques to silence a gene was via targeting the coding region only. In this instance, Dr. Wang’s team utilized the RNAi technique to more efficiently knock down the gene via targeting both the coding region (making the RNA unstable) and noncoding region (blocking protein production), thereby making brain cancer and lung cancer cells two to three times more sensitive to X-ray radiation.

“Inhibition of DNA repair has been tried using drugs that inhibit repair enzymes,” Dr. Wang stated. “This approach--combining targeted genes and combining targeted regions of one gene-- made it possible to efficiently knock down either gene and achieve a greater sensitivity to radiation.”

RNAi is a technique that is widely used in the laboratory. It could be useful clinically as well because of the targeted ability to silence particular genes, but is still experimental for use in humans. Andrew Fire and Craig Mello received the 2006 Nobel Prize in Medicine for the discovery that short pieces of RNA, when introduced into cells, can silence a stretch of genetic code. Artificially introduced RNA adopts mechanisms inside the cell that the cell naturally uses for regulation.

Dr. Wang added that her team’s strategy of combining two ways to knock a gene down may be useful in the laboratory, among a wide range of fields of biology. “It may be particularly suited to suppressing genes that are difficult to approach by simpler methods,” she commented.

Related Links:

Emory University’s Winship Cancer Institute



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.